Objective: to observe the clinical therapeutic effect of "salbutamol and phenergan" in the implementation of "children with cough variant asthma" through clinical experiments. Methods: 100 children...Objective: to observe the clinical therapeutic effect of "salbutamol and phenergan" in the implementation of "children with cough variant asthma" through clinical experiments. Methods: 100 children with cough variant asthma admitted from June 2019 to May 2020 were selected as the object of this study combined with the clinical research subjects of children with cough variant asthma, and were simultaneously divided into the control group and the observation group, and the actual records of the observation and textual research of the disease conditions of the related 100 children were well recorded. Among them, the control group mainly adopts the conventional treatment management measures, while the observation group adopts the clinical treatment implementation plan of "salbutamol and phenergan" to further analyze the optimization effect of the two groups of children in clinical treatment. Results: from the change after treatment, the maximum expiratory flow rate in the observation group was (87.8 ± 4.1) L/min;The change of high expiratory flow rate in the control group was (84.0 ± 4.2) L/min, and the comparison between the two groups was statistically significant (P < 0.05). To sum up, the clinical observation of the actual situation of the treatment of the two groups of patients, of which the maximum group's total effective rate of 94% was significantly higher than the control group of 84%;At the same time, the incidence of treatment after three months was observed, among which the incidence of observation of the other side was 96%(48/50)/ that of the control group was 84%(42/50). There were statistically significant differences between the two groups in the comparison of clinical treatment effect and incidence, P < 0.05. Conclusion: The treatment scheme of salbutamol and phenergan is beneficial to the disease control of children with cough variant asthma, which not only improves the therapeutic effect, but also can prevent the recurrence of the disease, and is worthy of further promotion and application.展开更多
文摘Objective: to observe the clinical therapeutic effect of "salbutamol and phenergan" in the implementation of "children with cough variant asthma" through clinical experiments. Methods: 100 children with cough variant asthma admitted from June 2019 to May 2020 were selected as the object of this study combined with the clinical research subjects of children with cough variant asthma, and were simultaneously divided into the control group and the observation group, and the actual records of the observation and textual research of the disease conditions of the related 100 children were well recorded. Among them, the control group mainly adopts the conventional treatment management measures, while the observation group adopts the clinical treatment implementation plan of "salbutamol and phenergan" to further analyze the optimization effect of the two groups of children in clinical treatment. Results: from the change after treatment, the maximum expiratory flow rate in the observation group was (87.8 ± 4.1) L/min;The change of high expiratory flow rate in the control group was (84.0 ± 4.2) L/min, and the comparison between the two groups was statistically significant (P < 0.05). To sum up, the clinical observation of the actual situation of the treatment of the two groups of patients, of which the maximum group's total effective rate of 94% was significantly higher than the control group of 84%;At the same time, the incidence of treatment after three months was observed, among which the incidence of observation of the other side was 96%(48/50)/ that of the control group was 84%(42/50). There were statistically significant differences between the two groups in the comparison of clinical treatment effect and incidence, P < 0.05. Conclusion: The treatment scheme of salbutamol and phenergan is beneficial to the disease control of children with cough variant asthma, which not only improves the therapeutic effect, but also can prevent the recurrence of the disease, and is worthy of further promotion and application.
